Chimeric Antigen Receptors Binding Nectin-4 for Cancer Treatment
Summary
The USPTO published patent application US20260091114A1 by Fred Hutchinson Cancer Center disclosing Chimeric Antigen Receptors (CARs) with binding domains that target Nectin-4, derived from murine antibody M22-321b41.1. The CARs are designed for expression in immune cells to treat Nectin-4-expressing cancers including bladder, breast, ovarian, esophageal, lung, colorectal, and pancreatic cancers. Application No. 19112145 was filed September 14, 2023.
What changed
The USPTO published a patent application disclosing chimeric antigen receptors (CARs) with Nectin-4 binding domains derived from the murine antibody M22-321b41.1. The CARs are engineered for expression in immune cells and intended for treating Nectin-4-expressing cancers. Named inventors are John K. Lee and Li-Ting Wu. CPC classifications include C07K 14/7051, C07K 16/2803, and related A61K therapeutic compositions.
This is a routine patent application publication containing no regulatory requirements or compliance obligations. The document provides public notice of the pending application and establishes a priority date of September 14, 2023. Companies developing CAR T-cell or immunotherapy products targeting Nectin-4 should review this application for potential patent landscape implications.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CHIMERIC ANTIGEN RECEPTORS BINDING NECTIN-4
Application US20260091114A1 Kind: A1 Apr 02, 2026
Assignee
Fred Hutchinson Cancer Center
Inventors
John K. Lee, Li-Ting Wu
Abstract
Chimeric antigen receptors (CAR) with a binding domain that binds Nectin-4 are disclosed. The Nectin-4 binding domain can be derived from the murine antibody M22-321b41.1. The CAR disclosed herein can be expressed by an immune cell to be used in the treatment of Nectin-4-expressing cancers, such as bladder, breast, ovarian, esophageal, lung, colorectal, or pancreatic cancers.
CPC Classifications
A61K 40/4202 A61K 40/11 A61K 40/31 C07K 14/7051 C07K 16/2803 C07K 2317/622
Filing Date
2023-09-14
Application No.
19112145
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Peptides (C07K) publishes new changes.